Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Ca...(the timingprogress and results of the cl...),Health

Date:8/26/2007

the timing, progress and results of the clinical development, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

References

1. World Health Organization. Hepatitis B. Available at:

http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/.

Accessed April 10, 2007.

2. Penn State Milton S. Hershey Medical Center College of Medicine.

Malignant Hepatoma. Available at:

http://www.hmc.psu.edu/healthinfo/m/malignanthepatoma.htm. Accessed

April 10, 2007.

3. International Agency for Cancer Research. GLOBOCAN 2002. Available at:

http://www-dep.iarc.fr. Accessed April 23, 2007.

4. Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and

Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress,

Lyon, 2004. Available at: http://www-dep.iarc.fr<
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; Onyx Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
2. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
3. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
7. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
8. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
9. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
10. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
11. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer